Recent investigations into the role of the chemokine CXCL10 (also known as IP-10) in hepatitis C virus (HCV) infection highlight the growing demand for highly selective antibodies in studies of inflammation and immunoregulation.

While CXCL10 is known as a proinflammatory chemokine that is responsible for recruiting activated lymphocytes to the liver in HCV infected patients, elevated levels of CXCL10 were surprisingly shown to be a negative prognostic marker for response to therapy.

HCV infects nearly 170 million individuals worldwide. Studies show that the virus is cleared through HCV-specific CD8+ T cells, plus some NK cell activity. Curative treatment is successful in 40-80% of patients (numbers vary depending on viral genotype) with chronic infection following a combination regime of pegylated IFN-α2 and ribavirin.

The pathological mechanisms that prevent viral clearance are still uncertain, but the chemokine CXCL10 has been implicated. This circulating molecule binds to the cell surface receptor protein CXCR3 found especially on activated T lymphocytes and NK cells. A second step sees the flexible N-terminal tail of CXCL10 bind and trigger internal modulatory pathways. If active DPP4 cleaves the N-terminal tail, the CXCL10 molecule can still bind to the receptor but does not induce signaling. This form acts as an antagonist for the bioactive full length chemokine, thought to result in less powerful inflammatory responses.

A collaboration of French institutes solved this puzzle when they showed that blood and plasma samples from chronic HCV patients contained CXCL10 in an antagonistic form; this variant can still bind to its target receptor but does not trigger cell signaling. They also found that this antagonist form is a truncated version of active CXCL10, generated when the enzyme DPP4 (CD26) cleaves the first two amino acids from the N-terminus of the chemokine molecule.

The scientists made their discoveries using recombinant antibodies isolated from the Human Combinatorial Antibody Library (HuCAL®). The specifically developed Fab antibodies showed high selectivity, binding either to full length CXCL10 or to the truncated chemokine, but not to both despite the close similarity between the two target forms. The team developed and validated ‘three-plex’ immunoassays, which they then used to investigate the in vitro and in vivo dynamics and activity of CXCL10 and DPP4.

About HuCAL
The HuCAL library has been created by mirroring the structural repertoire of the human immune system through the generation of master genes representing the various subclasses of human immunoglobulin. Sequences for the highly diversified complementarity determining regions (CDRs) of the antibody binding sites are synthesized by using trinucleotides. These ‘cassettes’ are combined to create antibody genes that code for some 45 billion unique fully human antibodies. HuCAL technology is well published and proven and has been used by the Bio-Rad custom antibody team to generate antibodies for research and diagnostic applications since 2004.
Selection of specific antibodies is performed in vitro, which allows researchers to generate single antibodies that can differentiate between antigens with minimal molecular differences such as the two amino acid truncation of CXCL10. As the sequence of any selected antibody is known, it is possible to reproduce the genes synthetically if needed. This sequence back up secures the future supply of the antibody and recombinant production methods ensure there is a high level of consistency between batches.

**Guided selection strategies to identify antibodies against closely related antigens**

Scientists from Bio-Rad isolated antibodies with selective binding to the agonist or antagonist forms of CXCL10. First, clones were isolated from the HuCAL library that recognized the truncated 7 amino acid N-terminal neoepitope but not the 9 amino acid peptide representing the native protein sequence. These antibodies were selected by three rounds of panning the library on the short peptide only (alternating between BSA and transferrin conjugates) and by blocking the library with the 9 amino acid peptide coupled to BSA (Figure 1).

The HuCAL PLATINUM library contains more than 45 billion human antibodies against virtually every possible antigen or epitope. Sophisticated serial screening can isolate antibodies that have unique specificity for a native protein or cleavage product that may be truncated by just a few amino acids.

To find the antibody specific for the full length protein and not the truncated form, an alternating panning was carried out on the 9 amino acid peptide coupled to BSA and the full length protein (Figure 2), to enrich antibodies binding to the folded protein. In this case the library was blocked with the 7 amino acid peptide coupled to BSA (not shown).

**Fig. 1. Guided selection with blocking.**
The 9 amino acid peptide is used to remove crossreactive antibodies (counter-selection).

**Fig. 2. Guided selection with alternating antigens.**
The antigen is alternated during the three rounds of selection, thereby enriching antibodies that bind to both antigens. Primary screening on both antigens is used to confirm the desired cross-reactivity.
Screening by direct ELISA was used to select the final clones for assay development, followed by sandwich ELISA to show antibody specificity to the whole and truncated versions of CXCL10 (Figure 3).

The team used its isolated unique antibodies in fluorescent microsphere-based ‘three-plex’ assays that simultaneously quantified total, whole and truncated (antagonist) CXCL10. One of two assays developed by the team has been CLIA certified.

**Key findings**

The high specificity of the HuCAL-derived antibodies and their incorporation into a validated, quantified assay has enabled the team to publish the evidence that chemokine antagonism may contribute to some patients being unable to clear HCV even with treatment. Although CXCL10 secretion is high in these patients, elevated DPP4 activity leads to rapid cleavage of the N-terminal of CXCL10. This destroys the molecule’s ability to activate cell signaling pathways when it binds to its target immunoreceptor.

Interestingly, the differential assay also distinguished between the two forms of CXCL10 in urine samples taken from patients with non-muscle invasive bladder carcinoma being treated by intravesical bacilli Calmette-Guérin (BCG) therapy. Corresponding high levels of urinary DPP4 suggest that chemokine antagonism may also diminish the inflammatory response behind this treatment.

**Conclusion**

Biomarker discovery is high on the agenda for biomedical researchers as they search for more precise diagnostics and predictors for treatment outcomes. Validation of surrogate markers will help to improve clinical outcomes, support drug trials and provide an essential platform for more personalized medicine.

**References**


Figure 3 is reproduced with permission from Casrouge A et al. (2012). Discrimination of agonist and antagonist forms of CXCL10 in biological samples. Clin Exp Immunol 167, 137-148. © 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology. Published by John Wiley and Sons.
HuCAL generated antibodies are not intended for use in humans, and may not be used for therapeutic, prophylactic or palliative purposes. Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. HuCAL and HuCAL PLATINUM are trademarks of MorphoSys AG. All trademarks used herein are the property of their respective owner.